endocrine:glp1:start
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| endocrine:glp1:start [2026/02/13 00:14] – [GLP-1 vs SGLT2] andrew2393cns | endocrine:glp1:start [2026/02/13 00:14] (current) – [Clinical Pearls] andrew2393cns | ||
|---|---|---|---|
| Line 116: | Line 116: | ||
| ===== Clinical Pearls ===== | ===== Clinical Pearls ===== | ||
| - | ✔ Glucose-dependent insulin release | + | * ✔ Glucose-dependent insulin release |
| - | ✔ Promote weight loss | + | |
| - | ✔ Reduce ASCVD events | + | |
| - | ✔ Low hypoglycemia risk | + | |
| - | ✔ Not primary HF therapy | + | |
| - | ✔ Complementary to SGLT2 inhibitors | + | |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | ||
endocrine/glp1/start.txt · Last modified: by andrew2393cns
